Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A liver protein may hold the key to fighting Alzheimer's. Scientists discovered that a liver-derived protein called APOA1 crosses the blood-brain barrier and helps regulate cholesterol in brain cells, supporting healthy synapses. In Alzheimer's mice, this transport pathway was disrupted early in the disease — but boosting APOA1 production in the liver reduced brain inflammation, lowered amyloid buildup, and improved memory.
A liver protein may hold the key to fighting Alzheimer's
Scientists have found that the blood-brain barrier (BBB) isn't just a wall — it's an active gateway that shuttles proteins from the bloodstream into specific brain cells. A new study published in Cell identified 92 circulating proteins that cross the BBB, many originating from the liver. One standout: apolipoprotein A1 (APOA1), a liver-derived protein that travels to astrocytes (brain support cells) and helps regulate cholesterol metabolism, ultimately strengthening neuronal synapses.
In Alzheimer's disease mouse models, this APOA1 delivery system breaks down early — before widespread barrier damage occurs. When researchers boosted APOA1 production in the liver using a gene therapy vector, levels rose in the blood and brain, leading to reduced inflammation, lower amyloid deposits in the hippocampus, better synaptic density, and improved spatial memory in the mice.
Key Takeaways
Why it matters: This research points to the liver-plasma-brain axis as a promising new therapeutic target for Alzheimer's — suggesting that treatments aimed at restoring or enhancing APOA1 delivery to the brain could one day help slow or prevent neurodegeneration.
